Ones To Watch News
Refine Search
Pharmaceutical
ParaPRO, a specialty pharma company focused on innovative anti-parasitic treatments, has announced the availability of Natroba (spinosad) Topical Suspension, 0.9%, the first product for scabies to be approved by the US Food and Drug Administration (FDA) in more than 30 years. 3 August 2021
Biotechnology
USA-based cell and gene therapy specialist Mustang Biotech’s shares edged up 1.4% to $2.83 in after-hours trading, following the0 announcement that the European Medicines Agency has granted Priority Medicines (PRIME) designation to MB-107, its lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (XSCID) in newly diagnosed infants, also known as bubble boy disease. 3 August 2021
Biotechnology
US biotech bluebird bio edged up 2% in early trading yesterday, after it announced an agreement with National Resilience to accelerate the early research, development, and delivery of next-generation cell therapies. 29 July 2021
Pharmaceutical
Germany-based biotech ATAI Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and UniQuest, Australia’s leading university technology transfer company commercializing the research of The University of Queensland (UQ), today announced the launch of InnarisBio Inc, to develop a novel sol-gel intranasal drug delivery technology to improve treatments for mental health disorders. 28 July 2021
Biotechnology
Swiss biotech AC Immune today announced that it is acquiring Austrian vaccine specialist Affiris’ portfolio of therapeutics targeting alpha-synuclein (a-syn), notably Affiris PD01, a clinically-validated active vaccine candidate for the treatment of Parkinson’s disease, as well as cash. 27 July 2021
Biotechnology
Chicago, USA-based antimicrobial resistance specialist Iterum Therapeutics announced a regulatory setback for its candidate, oral sulopenem, on Monday. 27 July 2021
Biotechnology
Shares of US biotech Denali Therapeutics closed down more than 15% at $54.14 yesterday, after it announced additional interim data from a Phase I/II study evaluating ETV:IDS (DNL310), an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system (CNS) and peripheral manifestations of Hunter syndrome (MPS II) that, while billed as positive, disappointed investors. 27 July 2021
Biotechnology
Germany’s BioNTech today announced the launch of its malaria project, which aims to develop a well-tolerated and highly effective malaria vaccine and implement sustainable vaccine supply solutions on the African continent. 26 July 2021
Pharmaceutical
Italian specialty pharma company Cassiopea today announced the signing of license and supply agreements with India’s Sun Pharmaceutical Industries for Winlevi (clascoterone cream 1%) in the USA and Canada. 26 July 2021
Biotechnology
Shares in USA-based microbiome therapeutics platform company Seres Therapeutics slumped 58% to $8.86 in heaving trading, which reached 10.1 million shares by late Thursday afternoon compared with the stock's daily average of about 827,000, according to data compiled by Yahoo Finance. 23 July 2021
Biotechnology
US biotech Arvinas on Thursday signed its most lucrative collaboration agreement, sending the firm’s shares up 9% to $84.51 by close of trading. 23 July 2021
Biotechnology
Dutch biotech firm Synaffix today announced the signing of a license and option agreement with ProfoundBio, an emerging oncology biotherapeutics company headquartered in China. 22 July 2021
Biotechnology
Swedish biotech Calliditas Therapeutics and Germany’s STADA Arzneimittel have entered into a license agreement to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN) in the European Economic Area (EEA) member states, Switzerland and the UK. 22 July 2021
Biotechnology
US clinical-stage biotech Magenta Therapeutics’ shares closed down more than 9% at $8.07 on Wednesday, after the company revealed it has received a clinical hold letter from the US Food and Drug Administration related to its Investigational New Drug Application (IND) filed in June 2021 to initiate a Phase I/II clinical trial of MGTA-117 in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). 22 July 2021
Biotechnology
USA-based microbiome company Vedanta Biosciences today announced the closing of a $68 million Series D financing. 21 July 2021
Biotechnology
US biotherapeutics company Gelesis is to go public via a merger with Capstar Special Purpose Acquisition, a special purpose acquisition company. 20 July 2021
Biotechnology
US oncology-focussed biotech Arcus Biosciences today announced that Dr Bill Grossman will transition out of his role as chief medical officer at Arcus and into a role at Gilead Sciences as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. 20 July 2021
Biotechnology
US biotech Amylyx Pharmaceuticals has announced the closing of an oversubscribed $135 million Series C financing. 20 July 2021
Biotechnology
Shares of California, USA-based cardiorenal specialist Ardelyx plunged more than 70% to $2.28 in after-hours trading on Monday, as the company revealed the US regulator is not ready to approve its tenapanor for dialysis patients. 20 July 2021
Biotechnology
Two doses of Ryoncil (remestemcel-L) at days 3-5 conferred durable survival benefit through at least 90 days in a pre-specified subgroup of patients under age 65, according to Australian biotech Mesoblast. 19 July 2021
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze